No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro

Radiation Oncology

Volumn 2, Issue 1, 2007, Pages

  Hermann, Robert M ^a   Schwarten, Dag ^a   Fister, Stefanie ^a   Grundker, Carsten ^a   Rave Frank, Margret ^a   Nitsche, Mirko ^a   Hille, Andrea ^a   Thelen, Paul ^a   Schmidberger, Heinz ^b   Christiansen, Hans ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35448970659     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-2-31     Document Type: Article

References (30)

1. Bolla M Gonzalez D Warde P Dubois JB Mirimanoff RO Storme G Bernier J Kuten A Sternberg C Gil T Collette L Pierart M: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Eng J Med 1997, 337:295-300. 10.1056/NEJM199707313370502
2. Bolla M Collette L Blank L Warde P Dubois JB Mirimanoff RO Storme G Bernier J Kuten A Sternberg C Mattelaer J Lopez Torecilla J Pfeffer JR Lino Cutajar C Zurlo A Pierart M: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study). Lancet 2002, 360:103-106. 10.1016/S0140-6736(02)09408-4 12126818
3. Pilepich MV Winter K John MJ Mesic JB Sause W Rubin P Lawton C Machtay M Grignon D: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 50:1243-1252. 10.1016/S0360-3016(01)01579-6 11483335.
4. Van der Werf-Messing B Sourek-Zikova V Blonk DI: Localized advanced carcinoma of the prostate: Radiation therapy versus hormonal therapy. Int J Radiat Oncol Biol Phys 1976, 1: 1043-1048. 791909
5. Neglia WJ Hussey DH Johnson DE: Megavoltage radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1977, 2:1123-1127. 599063
6. Taylor WJ Richardson RG Hafermann MD: Radiation therapy for localized prostate cancer. Cancer 1979, 43:1123-1127. 10.1002/ 1097-0142(197903)43:3<1123::AID-CNCR2820430351>3.0.CO;2-F 85478
7. Fellows GJ Clark PB Beynon LL Boreham J Keen C Parkinson MC Peto R Webb JN: Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment: A Medical Research Council Study. Br J Urol 1992, 70:304-309. 1422689
8. Granfors T Modig H Damber JE Tomic R: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized trial. J Urol 1998, 159:2030-2034. 10.1016/S0022-5347(01)63235-X 9598512
9. Pollack A Salem N Ashoori F Hachem P Sangha M von Eschenbach AC Meistrich ML: Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys 2001, 51:1002-1007. 10.1016/ S0360-3016(01)01750-3 11704324
10. Hara I Miyake H Yamada Y Takechi Y Hara S Gotoh A Fujisawa M Okada H Arakawa S Soejima T Sugimura K Kamidono S: Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate. Int J Urol 2002, 9:322-328. 10.1046/ j.1442-2042.2002.00470_1.x 12269247
11. Joon DL Hasegawa M Sikes C Khoo VS Terry NH Zagars GK Meistrich ML Pollack A: Supra-additive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997, 38:1071-1077. 10.1016/S0360-3016(97)00303-9 9276374
12. Pollack A Ashoori F Sikes C Joon DL von Eschenbach AC Zagars GK Meistrich ML: The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int J Radiat Oncol Biol Phys 1999, 46:153-158. 10.1016/S0360-3016(99)00387-9
13. Granfors T Tomic R Bergh A Rydh M Löfroth PO Widmark A: After radiotherapy testosterone stimulation is unable to increase growth in the Dunning R3327-PAP prostate tumour. Urol Res 1999, 27:357-361. 10.1007/s002400050163 10550524
14. Kaminski JM Hanlon AL Joon DL Meistrich M Hachem P Pollack A: Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys 2003, 57:24-28. 10.1016/ S0360-3016(03)00539-X 12909211
15. Halmos G Arencibia JM Schally AV Davis R Bostwick DG: High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urology 2000, 163:623-629. 10.1016/S0022-5347(05)67947-5
16. Wells A Souto J Solava J Kassis J Bailey KJ Turner T: Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signalling. Clin Cancer Res 2002, 8:1251-1257. 11948140
17. Limonta P Dondi D Moretti RM Maggi R Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992, 75:207-212. 10.1210/jc.75.1.207 1320049
18. Jungwirth A Galvan G Pinski J Halmos G Szepeshazi K Cai RZ Groot K Schally AV: Luteinizing Hormone-Releasing Hormone antagonist cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate 1997, 32:164-172. 10.1002/ (SICI)1097-0045(19970801)32:3<164::AID-PROS2>3.0.CO;2-L 9254895
19. Gründker C Schlotawa L Viereck V Eicke N Horst A Kairies B Emons G: Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 2004, 151:141-149. 10.1530/eje.0.1510141 15248835
20. Fister S Gunthert AR Emons G Gründker C: Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res 2007, 67:1750-1756. 10.1158/0008-5472.CAN-06-3222 17308117
21. Dobkin-Bekman M Naidich M Pawson AJ Millar RP Seger R Naor Z: Activation of mitogen-activated protein kinase (MAPK) by GnRH is cell-context dependent. Mol Cell Endocrin 2006, 252:184-190. 10.1016/j.mce.2006.03.035
22. Dondi D Limonta P Moretti RM Marelli MM Garattini E Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994, 54:4091-4095. 8033142
23. Pagnini U Florio S Crispino L Pagnini G Colangelo D Rocco D Pacilio C Pacilio M Macaluso M Giordano A: Direct effect of a gonadotropin-releasing hormone agonist on the growth of canine mammary tumour cells. J Cell Biochem 2002, 85:470-481. 10.1002/jcb.10167 11967986
24. Nagayoshi J Higashi T Maruyama Y: Serum concentrations of flutamide and goserelin in a prostate cancer patient with obstructive nephropathy: A case report. Hinyokika Kiyo 1999, 45:543-546. 10500960
25. Wells A Souto JC Solava J Kassis J Bailey KJ Turner T: Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. Clin Cancer Res 2002, 8:1251-1257. 11948140
26. Dondi D Moretti RM Marelli MM Motta M Limonta P: Growth factors in steroid-responsive prostatic tumor cells. Steroids 1996, 61:222-225. 10.1016/0039-128X(96)00018-9 8733005
27. Gründker C Günthert AR Hellriegel M Emons G: Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells. Eur J Endocrinol 2004, 151:619-628. 10.1530/eje.0.1510619 15538941
28. Gottschalk AR Doan A Nakamura JL Stokoe D Haas-Kogan DA: Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int J Radiat Oncol Biol Phys 2005, 63:1221-1227. 10.1016/j.ijrobp.2005.08.014 16253776
29. Mu Z Hachem P Pollack A: Antisense Bcl-2 sensitizes prostate cancer cells to radiation. Prostate 2005, 65:331-340. 1586105 16015611 10.1002/ pros.20303
30. Truman JP Gueven N Lavin M Leibel S Kolesnick R Fuks Z Haimovitz-Friedman A: Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis. J Biol Chem 2005, 280:23262-23272. 1855286 15837784 10.1074/jbc.M503701200